Table 2.
Patients’ baseline characteristics according to progression status
| All subjects | |||
|---|---|---|---|
| No Progression | Progression | p value | |
| Patients, n | 117 | 117 | |
| Age (years), mean ± SD | 58.3 ± 10.7 | 61.3 ± 10.8 | 0.03 |
| Male sex, n (%) | 90 (77) | 96 (82) | 0.42 |
| BMI (kg/m2), mean ± SD | 27.2 ± 3.9 | 28.0 ± 4.0 | 0.11 |
| Exam interval (months), median (IQR) | 29.8 (18.8 - 42.8) | 34.1 (20.4 - 55.2) | 0.05 |
| Baseline SSS, median (IQR) | 5 (1 - 9) | 8 (2 - 14) | 0.01 |
| Clinical risk factors | |||
| Hypertension, n (%) | 58 (50) | 59 (50) | 1.00 |
| Diabetes, n (%) | 15 (13) | 15 (13) | 1.00 |
| Dyslipidemia, n (%) | 65 (56) | 60 (51) | 0.60 |
| Family history CAD, n (%) | 54 (46) | 45 (38) | 0.29 |
| Glucose intolerance, n (%) | 3 (3) | 7 (6) | 0.33 |
| Current smoker, n (%) | 16 (14) | 9 (8) | 0.20 |
| Past smoker, n (%) | 23 (20) | 32 (27) | 0.22 |
| Positive stress test, n (%) | 14 (12) | 12 (10) | 0.84 |
| History of MI, n (%) | 6 (5) | 12 (10) | 0.22 |
| Previous PCI, n (%) | 15 (13) | 35 (30) | 0.002 |
| Medication use | |||
| Beta-blockers, n (%) | 18 (15) | 17 (15) | 1.00 |
| ACEI/ARB, n (%) | 21 (18) | 24 (21) | 0.74 |
| Antiplatelet, n (%) | 18 (15) | 28 (24) | 0.14 |
| Statin, n (%) | 31 (26) | 28 (24) | 0.76 |
SD: standard deviation; BMI: body mass index; SSS: segment stenosis score; IQR: interquartile range; CAD: coronary artery disease; MI: myocardial infarction; PCI: percutaneous coronary intervention; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.